Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21224333 | 0.86 | SLC22A12 (0.34) | SLC22A12PIM1ESR1ESR2CHRM2 | |
| SCHEMBL15200324 | 0.85 | SLC22A12 (0.43) | SLC22A12MAOBESR1ESR2ALDH1A1 | |
| SCHEMBL5828736 | 0.83 | SLC22A12 (0.49) | SLC22A12MAOBALDH1A1KDM4EGAA | |
| SCHEMBL11886563 | 0.83 | ADORA3 (0.39) | MAOBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26244601 | 0.83 | CHRM2 (0.51) | MAOBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL118769 | 0.83 | SLC22A12 (0.40) | SLC22A12MAOBPIM1ESR1ESR2 | |
| SCHEMBL15199256 | 0.82 | SLC22A12 (0.41) | SLC22A12MAOBALDH1A1KDM4EGAA | |
| SCHEMBL21230500 | 0.82 | NPC1 (0.45) | SLC22A12MAOBALDH1A1KDM4EGAA | |
| SCHEMBL21225184 | 0.80 | MAOA (0.39) | SLC22A12MAOBPDE4APDE4BPDE4C | |
| SCHEMBL21224539 | 0.80 | SLC22A12 (0.40) | SLC22A12MAOBKDM4EGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | MAVERIX ONCOLOGY, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | MAVERIX ONCOLOGY, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | MAVERIX ONCOLOGY, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | MAVERIX ONCOLOGY, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210040136-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | MAVERIX ONCOLOGY, INC. | 2021-02-11 | — | — | US | disclosed |
| US-8283340-B2 | Treatment or prophylaxis of proliferative conditions | The University of the University of Dundee (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8283340-B2 | Treatment or prophylaxis of proliferative conditions | The University of the University of Dundee (GB) | 2012-10-09 | — | — | US | disclosed |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-07-26 | — | — | US | disclosed |
| EP-2424524-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
| WO-2010125350-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125350-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | BRCA1, CYP1B1, UGT1A1 | SLC22A12 1331/4885MAOB 270/4885PDE4A 1360/4885 |
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | ZYX, KRAS, SLC7A5 | SLC22A12 1745/4885MAOB 4134/4885PDE4A 1470/4885 |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | SLC22A12 960/4885MAOB 210/4885PDE4A 1058/4885 |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | SLC22A12 960/4885MAOB 210/4885PDE4A 1058/4885 |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | ZYX, SLC7A5, GMPS | SLC22A12 1130/4885MAOB 3534/4885PDE4A 338/4885 |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, BRCA1, UGT1A1 | SLC22A12 1022/4885MAOB 236/4885PDE4A 981/4885 |
| US-20210040136-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | ZYX, SLC7A5, GMPS | SLC22A12 1133/4885MAOB 3447/4885PDE4A 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.